Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors

Author： Medioni Jacques   Huchon Cyrille   >  

Publisher： Adis International

ISSN： 1174-5886

Source： Drugs in R&D, Vol.11, Iss.2, 2011-06, pp. : 147-157

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epirubicin plus vinorelbine useful in advanced breast cancer

By  

Inpharma, Vol. 1, Iss. 1453, 2004-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Vinorelbine/epirubicin vs AC in operable breast cancer

By  

Inpharma, Vol. 1, Iss. 1515, 2005-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Gemcitabine/epirubicin/docetaxel effective in early breast cancer

By  

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective: Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide

By Liubao Peng  

PharmacoEconomics, Vol. 27, Iss. 10, 2009-10 ,pp. : 873-886

Adis International

Access to resources Recommend Favorite

Gemcitabine plus vinorelbine superior in NSCLC

By  

Inpharma, Vol. 1, Iss. 1251, 2000-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite